CRIT BIT CORNER

Why is Giapreza Important?

Targets the RAAS System: Unlike catecholamines (e.g., norepinephrine, epinephrine) and vasopressin, Giapreza acts directly on the renin-angiotensin-aldosterone system (RAAS) to restore vascular tone [6].

Rapid Onset: Increases mean arterial pressure (MAP) within 5 minutes, making it ideal for refractory shock [4].

Catecholamine-Sparing Effect: Reduces the need for high-dose norepinephrine or vasopressin, which are associated with increased mortality and cardiac toxicity [3].

Bridges RAAS Deficiency: In septic and distributive shock, RAAS is often dysregulated, leading to high angiotensin I/II ratios and ACE dysfunction—Giapreza bypasses this by providing exogenous angiotensin II [6].

Indications

• Septic Shock [2].
• Distributive Shock (including vasoplegia) [9].
• Shock states with high catecholamine requirements (e.g., post-cardiopulmonary bypass vasoplegia) [9].
• Refractory Hypotension in Critically Ill Patients [5].

NB: Not indicated for hypovolemic shock—adequate fluid resuscitation must be confirmed before initiation [3].

Contraindications

There are no known contraindications to Giapreza use.

However, thromboembolic events are significantly increased, and concurrent venous thromboembolism (VTE) prophylaxis is recommended [3].

Side Effects / Adverse Reactions

• Thromboembolic Events (13%) – DVT, arterial thrombosis (Use VTE prophylaxis!) [3].
• Tachycardia (9%) – May require beta-blocker therapy if severe [3].
• Peripheral Ischemia (4%) – Monitor for limb changes, cool extremities [3].
• Fungal Infections (6%) – Possibly linked to immune suppression effects [3].
• Delirium (6%) – Consider dose adjustments in elderly or ICU delirium risk [3].
• Acidosis (6%), Hyperglycemia (4%) – Monitor ABGs and blood glucose [3].

Patient Overview

Age/Sex: 33-year-old Male

Admission Source: Transferred from ER to ICU for hemodynamic instability

Past Medical History:

• Alcohol Use Disorder
• Alcohol-Induced Pancreatitis
• Alcoholic Cirrhosis

Recent Medical History:

• Newly diagnosed alcoholic cirrhosis with multiple recent hospital admissions.
• Elevated liver function tests (LFTs), hepatosplenomegaly, and concern for spontaneous bacterial peritonitis (SBP) during the last admission.
• Started on antibiotics, discharged home on lactulose, and referred to transplant center for liver transplant evaluation.

Why Giapreza Worked

RAAS Dysfunction in Liver Disease

• Cirrhotic patients often have dysregulated RAAS due to reduced hepatic clearance of vasodilatory substances (e.g., nitric oxide).
• This leads to high renin levels but inadequate angiotensin II response, contributing to persistent hypotension.
• Giapreza bypasses this deficiency by directly providing angiotensin II, restoring vascular tone.

Catecholamine-Sparing Effect

• High doses of Levophed and Phenylephrine can cause vasoconstriction-induced ischemia.
• Giapreza allowed down-titration of catecholamines, reducing the risk of end-organ hypoperfusion.

Rapid MAP Recovery

• Giapreza acts within minutes.
• Its short half-life (<1 min) allows precise titration, crucial in critically ill patients.

Key Takeaways from this Case

Consider Giapreza in refractory shock, particularly when:

• Multiple vasopressors are required but MAP remains low.
• The patient has septic or mixed shock with liver dysfunction.
• Catecholamine doses are approaching toxic levels.

Monitor closely for:

• Thrombosis – High risk! Ensure DVT prophylaxis (e.g., heparin, LMWH).
• Peripheral ischemia – Monitor cap refill, pulses, extremity temperature.
• Rapid BP changes – Frequent BP monitoring is critical.

Weaning Considerations

• Giapreza should be tapered off gradually to avoid rebound hypotension.
• Other vasopressors should be adjusted accordingly to maintain stability.

Conclusion

This case highlights the life-saving role of Giapreza in refractory mixed shock. By targeting the RAAS pathway, Giapreza provided immediate hemodynamic improvement, allowing successful vasopressor weaning in a critically ill patient with liver dysfunction and sepsis.

For nurses in the ICU, understanding when to use Giapreza, how to monitor patients, and how to titrate vasopressors is essential for optimizing patient outcomes in distributive shock.